132 related articles for article (PubMed ID: 37897912)
1. A GPX4 non-enzymatic domain and MDM2 targeting peptide PROTAC for acute lymphoid leukemia therapy through ferroptosis induction.
Niu F; Yang R; Feng H; Liu Y; Liu R; Ma B
Biochem Biophys Res Commun; 2023 Dec; 684():149125. PubMed ID: 37897912
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4.
Cai M; Ma F; Hu C; Li H; Cao F; Li Y; Dong J; Qin JJ
Bioorg Med Chem; 2023 Jul; 90():117352. PubMed ID: 37257255
[TBL] [Abstract][Full Text] [Related]
3. Dual degradation mechanism of GPX4 degrader in induction of ferroptosis exerting anti-resistant tumor effect.
Wang C; Zheng C; Wang H; Shui S; Jin H; Liu G; Xu F; Liu Z; Zhang L; Sun D; Xu P
Eur J Med Chem; 2023 Feb; 247():115072. PubMed ID: 36603510
[TBL] [Abstract][Full Text] [Related]
4. Exploiting Cancer Vulnerabilities by Blocking of the DHODH and GPX4 Pathways: A Multifunctional Bodipy/PROTAC Nanoplatform for the Efficient Synergistic Ferroptosis Therapy.
Yao L; Yang N; Zhou W; Akhtar MH; Zhou W; Liu C; Song S; Li Y; Han W; Yu C
Adv Healthc Mater; 2023 Oct; 12(26):e2300871. PubMed ID: 37204046
[TBL] [Abstract][Full Text] [Related]
5. Ugi reaction-assisted assembly of covalent PROTACs against glutathione peroxidase 4.
Zhu L; Hu S; Yan X; Zeng Q; Zhang B; Jiang L; Yao SQ; Ge J
Bioorg Chem; 2023 May; 134():106461. PubMed ID: 36924654
[TBL] [Abstract][Full Text] [Related]
6. Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells.
Lei M; Zhang YL; Huang FY; Chen HY; Chen MH; Wu RH; Dai SZ; He GS; Tan GH; Zheng WP
Sci Rep; 2023 Dec; 13(1):21916. PubMed ID: 38081931
[TBL] [Abstract][Full Text] [Related]
7. A potent GPX4 degrader to induce ferroptosis in HT1080 cells.
Song H; Liang J; Guo Y; Liu Y; Sa K; Yan G; Xu W; Xu W; Chen L; Li H
Eur J Med Chem; 2024 Feb; 265():116110. PubMed ID: 38194774
[TBL] [Abstract][Full Text] [Related]
8. De Novo Design of an Androgen Receptor DNA Binding Domain-Targeted peptide PROTAC for Prostate Cancer Therapy.
Ma B; Fan Y; Zhang D; Wei Y; Jian Y; Liu D; Wang Z; Gao Y; Ma J; Chen Y; Xu S; Li L
Adv Sci (Weinh); 2022 Oct; 9(28):e2201859. PubMed ID: 35971165
[TBL] [Abstract][Full Text] [Related]
9. [Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy].
Wu X; Zhao J; Gao Y; Yao Q; Xie J
Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3628-3643. PubMed ID: 37805843
[TBL] [Abstract][Full Text] [Related]
10. Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer.
Adams CM; Mitra R; Xiao Y; Michener P; Palazzo J; Chao A; Gour J; Cassel J; Salvino JM; Eischen CM
Cancer Discov; 2023 May; 13(5):1210-1229. PubMed ID: 36734633
[TBL] [Abstract][Full Text] [Related]
11. Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
Yang J; Li Y; Aguilar A; Liu Z; Yang CY; Wang S
J Med Chem; 2019 Nov; 62(21):9471-9487. PubMed ID: 31560543
[TBL] [Abstract][Full Text] [Related]
12. PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective.
Han X; Wei W; Sun Y
Acta Mater Med; 2022; 1(2):244-259. PubMed ID: 35734447
[TBL] [Abstract][Full Text] [Related]
13. MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment.
Vicente ATS; Salvador JAR
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232374
[TBL] [Abstract][Full Text] [Related]
14. ZX703: A Small-Molecule Degrader of GPX4 Inducing Ferroptosis in Human Cancer Cells.
Hu M; Li X; Wang L; Zhang Y; Sun Y; Hua H; Liu H; Cai T; Zhu D; Xiang Q
ACS Med Chem Lett; 2024 Mar; 15(3):406-412. PubMed ID: 38505849
[TBL] [Abstract][Full Text] [Related]
15. Intracellular Delivery of Glutathione Peroxidase Degrader Induces Ferroptosis In Vivo.
Luo T; Zheng Q; Shao L; Ma T; Mao L; Wang M
Angew Chem Int Ed Engl; 2022 Sep; 61(39):e202206277. PubMed ID: 35924720
[TBL] [Abstract][Full Text] [Related]
16. A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer.
Li G; Lin SS; Yu ZL; Wu XH; Liu JW; Tu GH; Liu QY; Tang YL; Jiang QN; Xu JH; Huang QL; Wu LX
Biochem Pharmacol; 2022 Dec; 206():115329. PubMed ID: 36309080
[TBL] [Abstract][Full Text] [Related]
17. Bufotalin induces ferroptosis in non-small cell lung cancer cells by facilitating the ubiquitination and degradation of GPX4.
Zhang W; Jiang B; Liu Y; Xu L; Wan M
Free Radic Biol Med; 2022 Feb; 180():75-84. PubMed ID: 35038550
[TBL] [Abstract][Full Text] [Related]
18. [Effect and Involved Mechanism of RSL3-induced Ferroptosis in Acute Leukemia Cells MOLM13 and Drug-resistant Cell Lines].
Cheng L; Jin X; Lu WY; Sun R; Cao YQ; Wei YX; Wang LQ; He XY; Yuan T; Meng JX; Zhao MF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1109-1118. PubMed ID: 34362489
[TBL] [Abstract][Full Text] [Related]
19. Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilience.
Lee J; Roh JL
Cancer Lett; 2023 Apr; 559():216119. PubMed ID: 36893895
[TBL] [Abstract][Full Text] [Related]
20. [Advances in the preclinical and clinical research of proteolysis targeting chimera].
Liu Z; Liu S
Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3615-3627. PubMed ID: 37805842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
